Public health implications of MRSA in Canada
============================================

* Upton D. Allen

Methicillin-resistant *Staphylococcus aureus* (MRSA) has become established in acute and long-term health facilities worldwide. Currently, 2 main categories are recognized: hospital-associated (HA-MRSA) and community-associated MRSA (CA-MRSA). Infections caused by CA-MRSA begin in the community in people who lack known HA-MRSA risk factors, including recent hospital contact, surgery, residence in a long-term care facility, dialysis or presence of invasive medical devices.1 CA-MRSA strains have emerged in community settings worldwide.2–4 Cases are most frequently described within reasonably well-defined populations, such as among children, military recruits, incarcerated people, men who have sex with men, sports teams and native populations, among others.5 In these groups, the spread of infection is likely facilitated by suboptimal hygiene, crowding, frequent skin-to-skin contact and the sharing of personal items that may become contaminated.

The 2 categories of MRSA have distinct characteristics. CA-MRSA strains exhibit resistance to fewer classes of antimicrobials than does HA-MRSA. CA-MRSA strains also exhibit specific virulence factors, notably the Panton–Valentine leukocidin genes,6 which produce cytotoxins capable of inducing severe tissue necrosis and leukocyte destruction. The CA-MRSA strains currently circulating can be distinguished with molecular typing methods, such as pulsed-field gel electrophoresis and multilocus sequence typing. Pulsed-field typing has indicated that among the more common lineages of MRSA that have been described, USA100 and USA200 are associated with HA-MRSA,7 whereas the USA400 and USA300 clones have been associated with most of the outbreaks of CA-MRSA in the United States.8,9 The USA300 clones are clearly of relevance to Canada, as indicated by Gilbert and colleagues' report in this issue of *CMAJ*.10

The distinction between the 2 types of MRSA infections will become less clear as CA strains become disseminated within health care institutions by nosocomial transmission and the HA strains are carried out into the community. Thus, people within community or health care settings could become infected with MRSA strains of either category. Current reporting and surveillance mechanisms in Canada do not always permit a clear distinction between the 2 categories of MRSA.

Although the overall burden of MRSA infection is currently less in Canada than in some North American regions, such patterns can change, as illustrated by the experience in Texas. At the Texas Children's Hospital (TCH), the percentage of strains of MRSA that were CA have increased each year. Methicillin-sensitive strains of *S. aureus* currently account for less than one-quarter of cases of community isolates of *S. aureus* there.11 Moreover, many of the MRSA infections result from the community onset of HA-MRSA.12 Thus, for that particular region, “the horses may have already left the starting gate” as far as the likelihood of control measures to be effective is concerned.

Recently, the US Centers for Disease Control and Prevention (CDC) released strategies for case management of MRSA in community settings, particularly of skin and soft-tissue infections.5 In Canada, it is not yet too late to attempt to control the dissemination of MRSA in the community. Educational efforts have been proposed that target communities that have experienced greater community carriage rates of MRSA (e.g., First Nations communities).13

Gilbert and colleagues10 describe the results of an investigation of an outbreak of CA-MRSA in a marginalized population in the Calgary Health Region (CHR). Their report is characterized by several features important to public health. First, the outbreak was associated with the USA300 strain of MRSA. This is the first reported Canadian outbreak caused by this strain, although strains of USA400 isolated from skin and soft-tissue infections in east-central Saskatchewan have been documented.14 Second, the people at highest risk of infection were those with histories of illicit drug use, homelessness or recent incarceration. They could therefore act as vectors for this strain of MRSA, to spread it to other urban areas, health care facilities, prisons and shelters. This concern illustrates the importance of the report by Gilbert's group. Third, the illnesses were relatively severe: a considerable proportion of the people infected required outpatient intravenous antibiotic therapy. The authors have suggested several hypotheses to explain the spread of the USA300 strain within the marginalized population, including close contact with self-treated draining boils, the sharing of drug paraphernalia and the congregation of colonized residents of crack houses, shelters for homeless people, detoxication centres and correctional facilities. The reasons for the spread of this strain are multifactorial and constitute an excellent example of how CA-MRSA strains can become disseminated in a community of people with characteristics that make control measures difficult to implement, and lead to amplification of the prevalence and transmission of these strains.

The occurrence of infections with MRSA in community settings has important implications for public health and the approach to case management of *S. aureus* infections. A pivotal consideration is the appropriate use of surveillance and reporting procedures to identify cases and early trends in order to guide the public health response. This may require a more structured and regulated approach to reporting and surveillance at the provincial as well as the national level.

Although CA-MRSA has been associated mostly with skin and soft-tissue infections, severe invasive infections can also occur.15 Given that the *S. aureus* pathogen is common, the advent of strains that are more virulent (CA-MRSA) or resistant to antibiotics (HA-MRSA) may herald the onset of more severe forms of common staphylococcal diseases (e.g., skin infections, pneumonias and osteomyelitis). Our approach to the management of these infections would need to change, with emphasis on early recognition and the need to target antibiotic therapy appropriately, with use of risk stratification strategies, culture results and susceptibility testing, as appropriate.

Data are lacking on the most effective strategies to control the spread of MRSA in community settings. However, certain approaches should be optimized through education, including attention to basic hygiene and wound care. In recent CDC recommendations, patient education was noted to be crucial in the management of people with MRSA-related skin and soft-tissue infections.5 If they cannot maintain adequate hygiene and wound care, it may also be necessary to impose restrictions on their activities (e.g., exclusion from daycare or athletic practice). Multifaceted control measures will need to be tailored to specific high-risk groups, such as those described by Gilbert and colleagues.

Collaborative efforts in public health should include veterinary facilities, as evidenced by a recent report indicating that MRSA transfer among some animals, such as horses, is of concern.16 The possibility of transmission between animals and humans has also been raised.17

It is not too late to attempt to control MRSA in Canada. The “hot zones” of MRSA in Canada need to be further defined. Are there others similar to those described in the Gilbert report?10 Research is needed to further define the epidemiologic and microbiologic characteristics of MRSA in community settings. Studies are also required to optimize the diagnosis, treatment and prevention of CA-MRSA. To this end, given that MRSA does not respect provincial, territorial or other jurisdictional boundaries, national collaborative efforts are required.

@ See related article page [149](http://www.cmaj.ca/lookup/volpage/175/149)

## Footnotes

*   This article has been peer reviewed.
    
    **Competing interests:** None declared.

## REFERENCES

1.  1. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant *Staphylococcus aureus* disease in three communities. N Engl J Med 2005;352:1436-44.
    
    [CrossRef](http://www.cmaj.ca/lookup/external-ref?access_num=10.1056/NEJMoa043252&link_type=DOI) 
    
    [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=15814879&link_type=MED&atom=%2Fcmaj%2F175%2F2%2F161.atom) 
    
    [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=000228145200007&link_type=ISI) 

2.  2. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant *Staphylococcus aureus* in Western Australia. J Hosp Infect 1993;25: 97-108.
    
    [CrossRef](http://www.cmaj.ca/lookup/external-ref?access_num=10.1016/0195-6701(93)90100-E&link_type=DOI) 
    
    [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=7903093&link_type=MED&atom=%2Fcmaj%2F175%2F2%2F161.atom) 
    
    [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=A1993MG09500004&link_type=ISI) 

3.  3. Taylor G, Kirkland T, Kowalewska-Grochowska K, et al. A multistrain cluster of methicillin-resistant *Staphylococcus aureus* based in a Native community. Can J Infect Dis 1990;1:121-6.
    
    

4.  4. Vandenesch F, Naimi T, Enright MC, et al. Community-acquired methicillin-resistant *Staphylococcus aureus* carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003;9:978-84.
    
    [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=12967497&link_type=MED&atom=%2Fcmaj%2F175%2F2%2F161.atom) 
    
    [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=000184500100013&link_type=ISI) 

5.  5. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA, and participants in the CDC Convened Experts' Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available: [www.cdc.gov/ncidod/dhqp/ar\_mrsa\_ca.html](http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html) (accessed 2006 May 30).
    
    

6.  6. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin–producing *Staphylococcus aureus* in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128-32.
    
    [Abstract/FREE Full Text](http://www.cmaj.ca/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiY2lkIjtzOjU6InJlc2lkIjtzOjk6IjI5LzUvMTEyOCI7czo0OiJhdG9tIjtzOjIwOiIvY21hai8xNzUvMi8xNjEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

7.  7. McDougal LK, Steward CD. GE, Chaitram JM, McAllister SK, Tenover FC. Pulsed-field gel electrophoresis typing of oxacillin-reisistant *Staphylococcus aureus* isolates from the United States: establishing a national database. J Clin Microbiol 2003;41:5113-20.
    
    [Abstract/FREE Full Text](http://www.cmaj.ca/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamNtIjtzOjU6InJlc2lkIjtzOjEwOiI0MS8xMS81MTEzIjtzOjQ6ImF0b20iO3M6MjA6Ii9jbWFqLzE3NS8yLzE2MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

8.  8. Chambers HF. Community-associated MRSA — resistance and virulence converge. N Engl J Med 2005;352:1485-7.
    
    [CrossRef](http://www.cmaj.ca/lookup/external-ref?access_num=10.1056/NEJMe058023&link_type=DOI) 
    
    [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=15814886&link_type=MED&atom=%2Fcmaj%2F175%2F2%2F161.atom) 
    
    [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=000228145200015&link_type=ISI) 

9.  9. Buckingham SC, McDougal LK, Cathey LD, et al. Emergence of community-associated methicillin-resistant *Staphylococcus aureus* at a Memphis, Tennessee children's hospital. Pediatr Infect Dis J 2004;23:619-24.
    
    [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=15247599&link_type=MED&atom=%2Fcmaj%2F175%2F2%2F161.atom) 
    
    [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=000222842000005&link_type=ISI) 

10. 10. Gilbert M, MacDonald J, Gregson D, et al. Outbreak in Alberta of community-acquired (USA300) methicillin-resistant *Staphylococcus aureus* in people with a history of drug use, homelessness or incarceration. CMAJ 2006;175(2):149-54.
    
    [Abstract/FREE Full Text](http://www.cmaj.ca/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiY21haiI7czo1OiJyZXNpZCI7czo5OiIxNzUvMi8xNDkiO3M6NDoiYXRvbSI7czoyMDoiL2NtYWovMTc1LzIvMTYxLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

11. 11. Kaplan SL, Hultén KG, Gonzalez et al. Three-year surveillance of community-acquired *Staphylococcus aureus* infections in children. Clin Infect Dis 2005;40:1785-91.
    
    [Abstract/FREE Full Text](http://www.cmaj.ca/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiY2lkIjtzOjU6InJlc2lkIjtzOjEwOiI0MC8xMi8xNzg1IjtzOjQ6ImF0b20iO3M6MjA6Ii9jbWFqLzE3NS8yLzE2MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

12. 12. Hultén KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care–associated *Staphylococcus aureus* infections in children. Pediatr Infect Dis J 2006;25:349-53.
    
    [CrossRef](http://www.cmaj.ca/lookup/external-ref?access_num=10.1097/01.inf.0000207404.50143.1e&link_type=DOI) 
    
    [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=16567988&link_type=MED&atom=%2Fcmaj%2F175%2F2%2F161.atom) 
    
    [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=000236920400012&link_type=ISI) 

13. 13. First Nations and Inuit Health Committee, Canadian Pediatric Society. Methicillin-resistant *Staphylococcus aureus* in First Nations communities in Canada. Paediatr Child Health 2005;10:557-9.
    
    [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=19668690&link_type=MED&atom=%2Fcmaj%2F175%2F2%2F161.atom) 

14. 14. Mulvey M, MacDougall L, Cholin B, et al. Community-associated methicillin-resistant *Staphylococcus aureus,* Canada. Emerg Infect Dis 2005;11:844-50.
    
    [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=15963278&link_type=MED&atom=%2Fcmaj%2F175%2F2%2F161.atom) 
    
    [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=000229307400009&link_type=ISI) 

15. 15. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant *Staphylococcus aureus* — Minnesota and North Dakota, 1997–1999. MMWR 1999;48:707-10.
    
    [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=21033181&link_type=MED&atom=%2Fcmaj%2F175%2F2%2F161.atom) 

16. 16. Weese JS, Rousseau J, Willey BM, et al. Methicillin-resistant *Staphylococcus aureus* in horses at a veterinary teaching hospital: frequency, characterization, and association with clinical diseases. J Vet Intern Med 2006;20:182-6.
    
    [CrossRef](http://www.cmaj.ca/lookup/external-ref?access_num=10.1892/0891-6640(2006)20[182:MSAIHA]2.0.CO;2&link_type=DOI) 
    
    [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=16496939&link_type=MED&atom=%2Fcmaj%2F175%2F2%2F161.atom) 
    
    [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=000235197500025&link_type=ISI) 

17. 17. Weese JS, Dick H, Willey BM, McGeer A, et al. Suspected transmission of methicillin-resistant *Staphylococcus aureus* between domestic pets and humans in veterinary clinics and in the household. Vet Microbiol 2006;115:148-55. Epub 2006 Feb 7.
    
    [CrossRef](http://www.cmaj.ca/lookup/external-ref?access_num=10.1016/j.vetmic.2006.01.004&link_type=DOI) 
    
    [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=16464540&link_type=MED&atom=%2Fcmaj%2F175%2F2%2F161.atom) 
    
    [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=000238411600015&link_type=ISI)